www.barrons.com
Open in
urlscan Pro
2600:9000:2250:e800:14:c68f:c40:93a1
Public Scan
URL:
https://www.barrons.com/articles/buy-moderna-stock-long-term-covid-vaccine-51643383455?mod=past_editions
Submission: On January 31 via api from CH — Scanned from DE
Submission: On January 31 via api from CH — Scanned from DE
Form analysis 1 forms found in the DOM
<form autocomplete="off">
<div id="scrim-from-wrap" class="input-wrap">
<label for="scrim-from">From</label>
<textarea id="scrim-from" readonly="readonly" disabled="disabled" type="text" autocomplete="off" autocorrect="off" autocapitalize="none"></textarea>
</div>
<div id="scrim-to-wrap" class="input-wrap">
<label for="scrim-to">To</label>
<input id="scrim-to" type="text" autocomplete="off" autocorrect="off" autocapitalize="none">
</div>
<div class="input-wrap">
<label for="scrim-message">Message</label>
<textarea id="scrim-message" class="msg" maxlength="500" type="text" autocomplete="off" autocorrect="off" autocapitalize="none"></textarea>
</div>
</form>Text Content
We've detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser. CHROME SAFARI FIREFOX We've detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser.GoogleFirefox Search News & Quotes Barron's TopicsStock PicksMagazineDataAdvisorPenta100 Years Subscribe Now |Sign In Barrons Moderna Faces Challenges Beyond the Covid Vaccine. Its Stock Is Still a Buy. Next: The Canary in the Coal Mine for College Enrollment * * * * Share This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barrons.com/articles/buy-moderna-stock-long-term-covid-vaccine-51643383455 * Biotech and Pharma * Feature MODERNA FACES CHALLENGES BEYOND THE COVID VACCINE. ITS STOCK IS STILL A BUY. * * * * -------------------------------------------------------------------------------- By Josh Nathan-Kazis Updated Jan. 28, 2022 10:50 am ET / Original Jan. 28, 2022 10:25 am ET * Order Reprints * Print Article A HEALTHCARE WORKER ADMINISTERING A VACCINATION FOR COVID-19 IN MUNICH. MODERNA HAS SOLD OR CONTRACTED TO SELL $36 BILLION WORTH OF ITS COVID-19 VACCINE SINCE THE START OF 2021. Michaela Handrek-Rehle/Bloomberg In 2019, four pharmaceutical giants shared virtually all of the $33 billion worth of vaccine revenue earned worldwide. Moderna (ticker: MRNA), meanwhile, had just 830 employees and no product sales. The pandemic has upended the vaccine business. Moderna has sold or contracted to sell $36 billion worth of its Covid-19 vaccine since the start... Subscribe or Sign In to continue reading -------------------------------------------------------------------------------- * Economy & Policy THE CANARY IN THE COAL MINE FOR COLLEGE ENROLLMENT * * * * -------------------------------------------------------------------------------- By Tolani Britton Jan. 31, 2022 5:00 am ET * Order Reprints * Print Article MULTIPLE FACTORS INCLUDING RISING COSTS, THE COVID PANDEMIC, AND CHANGES TO VIRTUAL LEARNING ARE COMPLICATING STUDENTS' DECISIONS TO GO TO COLLEGE. Dreamstime About the author: Tolani Britton is an assistant professor at the University of California Graduate School of Education. To attend college or not to attend college? In the face of high college costs, a global pandemic, numerous colleges offering primarily virtual classes, and rising wages for jobs that do not require a college education, the answer to this question is less clear than it might have been two years ago. But what makes sense for millions of individuals adds up to something less clear for the economy as a whole. Rates of college enrollment are declining, with estimates from the National Student Clearinghouse placing the decline at over 6.5% from fall 2019 to fall 2021. While some sectors, particularly the community college sector and public four-year colleges, have seen relatively larger declines in enrollment, almost all sectors have enrolled fewer students. It is important to note that the decreasing number of young persons enrolling in college is not a Continue reading Long Read -------------------------------------------------------------------------------- More from News Corp * Realtor.com Looking to buy your first home? You’ve come to the right place. * Wall Street Journal Investors Pile Into Gold, Seeking Safety From Market, Geopolitical Turbulence * Realtor.com Beige Is Back, Baby! Why This Neutral Color Is All the Rage Again * Realtor.com Sick of Seeing Your Ugly Propane Tank? Here Are 4 Designer Tips To Disguise It * PENTA Omega Kicks off 2022 With a 65th Anniversary Speedmaster Calibre 321 Close MODERNA FACES CHALLENGES BEYOND THE COVID VACCINE. ITS STOCK IS STILL A BUY. In 2019, four pharmaceutical giants shared virtually all of the $33 billion worth of vaccine revenue earned worldwide. From To Message SEND An error has occurred, please try again later. Thank you This article has been sent to Privacy Notice Cookie Notice Do Not Sell My Personal Information Copyright Policy Data Policy Your Ad Choices Subscriber Agreement & Terms of Use Barron's Archive Corporate Subscriptions Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. Barron's Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.